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1. Introduction 
The chapter presents updated results of immune-therapy in cutaneous melanoma in the 
light of the well-known resistance of this disease and the unrelenting efforts in overcoming 
it. The types of immune-therapy are correlated intrinsically with the efficacy immune-
markers utilized for thorough monitoring of treated patients.  
This life threatening disease has a recently reported increased incidence; in the United 
States, this continues to rise from 4% to 6% annually, despite steps towards primary 
prevention. Similar increases are being noted worldwide. It has been estimated that the 
current lifetime risk for developing invasive melanoma is 1 in 58 and it has been reported 
that over 8,000 Americans died of melanoma in 2009 (Rigel, 2010). These statistics highlight 
the need to find both new efficient therapies and improved markers for predicting disease 
evolution and therapy monitoring. 
Immune markers related to therapy monitoring are an important field for at least two 
reasons: the lack of good clinical responses in immune-therapy and the need for 
accumulating knowledge regarding the molecular processes that governate tumour 
progression (Riker et al., 2006). The intent of this chapter is to describe the immune-
therapies approaches in the intimate link with the immune markers as therapy efficacy 
monitoring. Immune monitoring is valuable not only for efficacy purposes but also for 
immune-tailored individualized therapy. 
2. Immune therapy – The ultimate solution in cutaneous melanoma? 
Up to date immunotherapy approaches that are in the stage of clinical development include: 
cytokines (IL-2, IFN, TNF, IL-7, IL-12, IL-21), cytokine-antibody fusion proteins or 
immunocytokines, whole tumour cell vaccines, genetically modified tumour cells, heat 
shock protein vaccines, peptide vaccines, dendritic cells pulsed with tumour antigens, 
tumour antigen-naked DNA vectors, recombinant viral vectors, adoptive transfer of cloned 
tumour antigen-specific T cells, Toll-like receptor ligands, antagonistic antibodies to 
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Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4), activating antibodies that target 
CD40 and CD137.  
All the therapeutical approaches seek to induce cytotoxic T-cell responses to tumours 
ranging from mono-specific immunotherapy, targeting only one specific tumour antigen, to 
polyvalent immunotherapy, which attempts to induce immune responses to multiple 
antigenic components, to gene-based therapy, which manipulates the immunogenicity of 
the tumour. Each of these therapies’ goal is to induce proliferation and differentiation of 
anti-tumoral antigen-specific memory T-cells.  
The FDA approved immune therapies for cutaneous melanoma comprise: IL-2, IFN and the 
most recent anti-CTL-4.  
2.1 Immune therapy and Immune markers 
There are still no validated immune markers to be used in monitoring immune-therapy in 
cutaneous melanoma, although it is the domain that would benefit the most from immune 
monitoring biomarkers and that surrogate immunologic markers of efficacy have not been 
reported thus far. 
One of the most used immune-marker in cutaneous melanoma is the “immune cell”. As an 
established disease with a high immune-suppressive background, peripheral immune cells 
were quantified both in relation to the monitoring of the patients immune status, and in 
therapy efficacy monitoring. We have previously published that peripheral blood 
CD4+/CD8+ ratio can monitor a good therapeutic response and that monitoring the 
dynamics of this subpopulations ratio can detect a good therapeutical response (Neagu et 
al., 2010). In the first reported study of high-risk melanoma patients immunized with gp100 
and tyrosinase peptides (Cassarino et al., 2006) no difference in nevi tissue was found 
regarding CD3, CD4, CD8, MHC-I, MHC-II, CD1a, HMB-45, MART-1, tyrosinase, but an 
increase in p53 and bcl-2 staining, in the nevi post-treatment has been found. Authors 
explain that activating melanoma-specific T cells for preventing melanoma recurrence a 
response mediated by p53 and bcl-2 is triggered in benign melanocytes (Cassarino et al., 
2006). Another group showed that following transcutaneous delivery, gp100 vaccination 
activates Langerhans cell and antibody production, markers of definitely immune activation 
(Frankenburg et al., 2007). 
In a phase I/II trial for melanoma vaccine comprising six melanoma-associated peptides 
(MAGE proteins, MART-1/MelanA, gp100, and tyrosinase), patients’ follow-up was 
performed using the in vitro proliferation of CD4+ lymphocytes. After vaccination, the 
monitoring of a good response was marked by an increased proliferation of T cells to 
relevant peptides in over 80% of patients correlated with good clinical response as well 
(Slingluff et al., 2008). Another study enrolling stage III/IV melanoma patients showed the 
data regarding patients vaccinated with Melan-A/Mart-1 peptide and Klebsiella outer 
membrane protein p40 as an adjuvant. In this trial the therapy was monitored by ex vivo 
analysis of Melan-A/Mart-1 specific CD8 T cells. Increased percentages of T cells, 
memory/effector T cell differentiation, positive IFN-gamma and antibody responses to p40 
were observed in all patients and positive clinical response in half of the treated patients 
(Lienard et al., 2009). 
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3. Immune-therapy – Ups and downs 
Each of the immunosuppressive mechanisms that underlie cutaneous melanoma 
development can be a target for clinical manipulation and it is obvious that immune–related 
parameters are useful in immunotherapy monitoring of the melanoma.  
3.1 Immunomodulatory antibodies  
Therapeutic antibodies induce cellular/complement-dependent cytotoxicity against tumour 
cells, or can modify immune responses by blocking the inhibitory signal pathways or 
stimulating the excitatory signal pathways.  
The surface molecules involved in this type of therapy are CD28, CTLA-4 (CD152), Toll-like 
receptor and many more. Both clinical and preclinical data indicate that CTLA-4 blockade 
using anti-CTL-4 antibodies results in direct activation of CD4+ and CD8+ effector cells in 
melanoma. Immune cells as parameters for immune-therapy efficacy should be evaluated in 
terms of progression-free survival and overall survival. 
In a very comprehensive recent paper (Joel et al., 2010) it was demonstrated that the 
receptors for the Fc region of the antibodies FcγR (FcγRIIB) expresed by the tumour act as 
„decoy receptors”, binding the IgGs that have an anti-melanoma action. Through this 
mechanism, the Fc recognition by the effector cells is hindered and the tumour escapes the 
immune effectors and can evolve toward metastasis. This group demonstrated that FcγRIIB 
inhibits in vitro antibody dependent cell cytotoxicity. It seems that FcγR suffer a selection 
process during the metastasis and that if the cutaneous melanoma evolves, their expression 
increase in the liver or in the lymph nodes. The FcR action is described in its dual mode as 
follows: FcγRIIB1 are not detected in melanocytes and have a low expression in primary 
tumours, while FcγRIIB1 is highly expressed in metastatic tumours in spleen and lymph 
nodes (Cassard et al., 2008). Knowing the potential of these receptors to modulate the 
immune response, therapeutic antibodies with an optimized Fc region can trigger an 
increased Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Antibody Dependent 
Cell Phagocytosis (ADCP) and Complement Dependant Cytotoxicity (CDC). The authors 
propose (Joel et al., 2010) to lower the Fc binding capacity to the FcγRIIB and to increase Fc 
binding to FcγRIIIA and FcγRI. It is of high probability that these improvements could 
trigger an enhanced efficiency of therapeutical anti-melanoma antibodies.  
3.1.1 Targeting cytotoxic T-lymphocyte antigen-4 
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is expressed by activated T cells and 
a subset of regulatory T cells being a co-inhibitory molecule. Its physiological role is to 
maintain an immune homeostasis by limiting T cell responses and inducing tolerance to self 
(Yuan et al., 2008). CTLA-4 has binding affinity for the B7 surface molecules of antigen-
presenting cell (APC), its affinity exceeding that of CD28. The binding induces T-cell anergy 
and inhibits secretion of mainly IL-2. When CD28 is bound, costimulatory pathways are 
triggered and T-cell proliferation and IL-2 production are enhanced (Weber, 2008). 
Therefore, this type of cell has a crucial negative role in the development of cutaneous 
melanoma. 
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Antibodies targeting CTLA-4, in their therapeutical form of ipilimumab and tremelimumab, 
have proven good clinical results. From early-phase clinical trials anti-CTLA-4 antibodies 
showed good results in melanoma and manageable toxicities. Then in phase II overall and 
long-term survival were increased in combined or in individual therapies (Tarhini et al., 
2010). Recently published results from a phase III clinical trial (ClinicalTrials.gov number, 
NCT00324155) (Robert et al, 2011) performed in several centres and institutes showed that in 
untreated metastatic melanoma overall survival of patients receiving ipilimumab plus 
dacarbazine was significantly longer compared to the other arms of the clinical trial. Side 
effects did not occur in the ipilimumab-dacarbazine group. This year, FDA approved 
ipilimumab and it was considered the „major breakthrough” in cancer immunotherapy. 
Side effects in anti-CTLA-4 therapy are named "immune-related adverse events" (irAEs). 
IrAEs mainly include digestive related negative effects, dermatitis, hepatitis and 
endocrinopathies, among other occasionally reported ones. It is clear that irAEs are the 
direct consequence of CTLA-4 blockade but can be managed by the physician (Phan et al., 
2008; Di Giacomo et al., 2010). 
The markers involved in this type of immunotherapy are several and compile both 
soluble/circulatory and tissue related groups. Therefore, anti-CTLA-4 treatment was 
monitored through Treg evaluation (Menard et al., 2008). After this therapy, the effector and 
memory CD4+ and CD8+ T-cell pool and TCR-dependent T-cell proliferation were restored. 
In this case, free survival and overall survival were directly correlated with the resistance of 
peripheral lymphocytes to Treg-inhibitory effects (Menard et al., 2008). The authors state 
that the biological activity marker of memory T-cell resistance to Treg resulting from anti-
CTLA-4 treatment is a good efficacy marker (Langer et al., 2007). At the tissue level, after 
anti-CTL4 treatment diffuse intra-tumoral infiltrates of CD8+ T cells correlated with good 
clinical outcome of the patients. Moreover patients with regressing tumours had an 
increased frequency of CD8+ cells with/without a concomitant increase in CD4+ cells 
(Neagu et al., 2010). 
Immunomodulatory therapy in melanoma needs thorough efficacy monitoring in both 
circulatory and tissue immune markers. 
3.2 Dendritic cell therapy  
Skin’s immune system has several cellular components, mainly regulatory T cells, natural 
killer T cells (NKT), and distinct subsets of immature and mature dendritic cells (DCs). All 
these cellular components comprise the immunosuppressive network (Rabinovitch et al., 
2007). DCs are more therapy tools than actual immune-markers. The reason is that DC 
release large quantities of dexosomes, their function being the transfer of antigen-loaded 
MHC class I / II and other associated molecules, to naive DC potentially leading to the 
amplification of the cellular immune response (Delcayre et al, 2005). Few years ago, using 
these DC “products” – dexosomes, two phases I clinical studies were published. In these 
studies, the monitoring was performed using T and NK cells as markers for cellular immune 
responses (Escudier et al., 2005; Hao et al., 2006). Dexosomes (Dex) are stable and carry 
defined proteins and lipids that can be standardized. The authors report that they could 
generate 10 vaccines of NK cell-stimulating Dexosomes. Using these dexosomes, melanoma 
patients can be boosted for DC-mediated T- and NK-cell responses (Viaud et al., 2010). 
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One of the first pilot trials using DC pulsed with autologous tumour lysate has shown that 
among all the advanced cancer patients entering the study one melanoma patient with 
extended metastases had a partial response lasting 8 months, while seven patients were 
stable for more than 3 months, and 7 had progression of the disease. Dendritic cells 
immune-therapy can induce a cell-mediated antitumour immune response in patients 
giving good clinical outcome (Mayordomo et al., 2007). In another study, isolated DCs were 
activated with CD40L, loaded with antigenic melanoma peptides and then injected into 
patients with resected melanoma. The patients were monitored for antigen-specific immune 
responses, namely skin reactions to peptides alone or peptide-pulsed DCs and circulating T-
cells responses (Davis et al., 2006). 
When vaccinated with DC, clinical investigators monitor the efficacy by the presence of 
vaccine-related tumour antigen-specific T cells in delayed type hypersensitivity (DTH) skin 
biopsies, in correlation to the clinical outcome. Punch biopsies taken from positive DTH 
sites proved clusters of CD2+ and CD3+ infiltrating cells, out of which over 50% were CD4+, 
the rest being CD8+ T cells (Aarntzen et al, 2008). 
It seems that there is an effervescent period of publication on dendritic cell therapy in 
cutaneous melanoma, but all the papers underlie some crucial points in using DC therapies. 
When using ex vivo generated DC, the effective migration of DCs to the T-cell areas in the 
lymph node is necessary; therefore, adding inflammatory cytokines would be beneficial 
(Aarntzen et al, 2008). Moreover, the addition of synergistic immunomodulatory agents to 
enhance immunogenicity (Erdmann & Schuler-Thurner, 2008) can enhance the clinical 
response.  
Monitoring the DC therapy comprises several steps to be taken. The inoculated DCs have to 
be monitored for their migratory potential to the tumour site. It is commonly agreed on the 
efficacy monitoring of the vaccine by detecting T-cell responses in vaccinated patients using 
biopsies derived from DTH sites in good correlation with the clinical outcome in melanoma 
patients (Aarntzen et al, 2008). 
3.3 Vaccines with melanoma antigens 
The processes that induce effective antitumour immunity by cancer vaccines implie several 
events: antigen delivery to antigen-presenting cells, migration of dendritic cells that carry 
the processed antigen to draining lymph nodes, antigen presentation to circulating T cells 
that enter the lymph nodes through the high endothelial venules, expansion of antigen 
reactive T-cells in the lymph nodes, dissemination of specific T-cells to tumour site, and 
tumour destruction by activated tumour-reactive T-cells (Slingluff Jr et al., 2008). 
The vaccines that were built until now against melanoma are based on strategies for 
activating the protective immunity by Tregs depletion and blockade of T-cell inhibitory 
molecules such as CTLA-4. All these approaches have developed multiple new 
proteomic/genomic tools to monitor immune responses in vaccinated patients. Several 
published clinical trials emphasized that melanoma antigen vaccination should be 
monitored using peripheral immune cells as the principal parameter. Some types of 
vaccination with melanoma-associated antigens will be highlighted in this section. 
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Developing cancer vaccines implies complex monitoring of the immune responses. Firstly, 
the efficacy of the vaccine in inducing/augmenting a specific T-cell response has to be 
tested. Secondly, the spontaneous tumour-directed immune responses, the functional 
characteristics of T-cell responses and, last but not least, the relationship between immune 
monitoring assay results and clinical end points have to be evaluated (Neagu et al, 2010).  
Giving a three decades view on cutaneous melanoma vaccination, important points have 
been highlighted (Sondak et al., 2006). Some of the vaccines, in late stages of clinical trials 
were discontinued due to regulatory and commercialization technicalities. Vaccines from 
autologous samples are reduced to patient groups still having accessible, surgically 
removable and sufficient tumour tissue for a complete treatment. Vaccines of allogeneic 
source can have common antigens, but they can lack the actual individual molecular 
particularities of an autologous tumour (Sondak et al., 2006).  
In a review of the National Cancer Institute’s experience with 440 patients (mostly 
melanoma patients) receiving 541 different vaccines, only 4 complete and 9 partial responses 
were seen, for an overall response rate of 3% (Rosenberg et al., 2004). A randomized 
comparison of a peptide-pulsed dendritic cell vaccine to the cytostatic agent dacarbazine 
(DTIC) in patients with advanced melanoma showed similarly low levels of objective 
response for the vaccine; the median time to progression and a median survival was 
relatively the same when DTIC alone was used (Rosenberg et al., 2004). 
One of the largest randomized clinical trials involving vaccines for the adjuvant therapy of 
melanoma was published several years ago. The trial compared a GM2 ganglioside vaccine 
(GMK vaccine, Progenics, Tarrytown, NY) to high-dose IFN in the adjuvant therapy of 
patients with resected melanoma at high risk of recurrence. In this trial, antibody responses 
to the vaccinated ganglioside were achieved by many patients. Unfortunately, the overall 
results were far more better for IFN treatment in both relapse-free and overall survival 
(Kirkwood et al., 2001, 2004) and the clinical trial was stopped. Then two randomized trials 
of a polyvalent whole cell melanoma vaccine (Canvaxin, CancerVax, Carlsbad, CA) were 
performed on patients with resected stage III and IV melanoma (an even higher-risk 
population than in the aforementioned ganglioside study); they were also stopped early 
because of a poor vaccine efficacy (Cancer Vax Corporation, 2005). 
A different polyvalent melanoma vaccine phase III trial (Melacine, Corixa, Seattle, WA) was 
conducted in patients with resected stage II melanoma. Analyzing the data, an effect of the 
vaccine on relapse-free survival (Sosman et al., 2002) and overall survival (Sondak et al., 
2004) for vaccine-treated patients expressing HLA antigens (HLA-A2 or HLA-C3) was 
obtained. This subset of patients (over half of the enrolled patients) was intended to be 
followed in order to verify the results, probably a follow-up of several years. In the end, the 
manufacturer of this vaccine simply decided not to support the development of Melacine.  
3.3.1 Autologous tumour vaccines  
Autologous vaccines derived from the patient’s own tumour have the main advantage of 
containing unique or rare tumour antigens that develop during mutational events. 
Autologous tumour vaccines are designed as appropriately HLA-matched for optimum 
antigen presentation to T lymphocytes host. Until recently, no autologous melanoma 
vaccine had ever been successfully tested in a phase III clinical trial. A phase III clinical trial 
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using heat shock proteins (HSP) extracted from autologous tumour (Oncophage, Antigenics, 
New York, NY) was developed. In the cell, these proteins act as ‘‘chaperones’’ for peptide 
antigens and have the potential to present tumour antigens to the immune system (Rivoltini 
et al., 2003; Lewis, 2004). Even though the preliminary results indicated no statistically 
significant effect for the heat shock vaccine compared with the physician’s choice of therapy, 
an intriguing observation of this trial is that the group of patients with M1 stage of disease 
treated with the vaccine, lived longer than those receiving other therapy, although not 
significant (Antigenics press release, 2005). 
3.3.2 Allogeneic vaccines  
A different type of vaccine developed in parallel with the previously presented one, are the 
allogeneic vaccines. These are composed of intact or modified melanoma cells from other 
patients selected for the presence of shared antigens found on a large percentage of 
melanomas. Compared with autologous tumour vaccines, the allogeneic ones have 
significant advantages in terms of availability for patients in all stages of the disease, and 
providing the capability to administer multiple vaccinations over an extended period. They 
may also be more naturally recognizable by the patient’s immune system than an 
autologous cell preparation. However, they may lack unique or rare antigens that could be 
important antigenic targets in any given patient’s melanoma.  
Canvaxin is a polyvalent irradiated melanoma auto/allo vaccine, originally developed by 
Dr. Donald Morton and commercially developed by CancerVax in partnership with Serono 
(Geneva, Switzerland) (Hsueh & Morton, 2003; Motl, 2004). This vaccine has been studied in 
two multi-centre randomized phase III trials in patients with resected stage III and IV 
melanoma. Recently, the Data Safety Monitoring Board overseeing these two studies 
determined that the trials were unlikely to provide efficacious results and the protocols were 
discontinued. The authors’ state that there are multiple reasons for a vaccine to prove its 
usefulness in earlier stage patients compared with the ones diagnosed in later stage disease 
(Salazar & Disis, 2005). Firstly, increasing evidence suggests that tumour progression leads 
to increased immunosuppression mechanisms directly mediated by tumour cells and/or by 
their microenvironment. The immune suppression is also induced by the presence of 
increasing numbers of Tregs (Viguier et al., 2004). Moreover, increasing numbers of tumour 
cells are increasingly likely to express antigenic heterogeneity that would limit the ability of 
an induced immune response to completely eradicate the tumour (Riker et al., 1999). Finally, 
in a patient with a relatively high residual tumour burden (patients stage IV melanoma), 
tumour progression could readily occur during the period required for induction of an 
immune response post-vaccination. In that case, the vaccination “failure” conclusion is not 
true as it did not have the chance to even naturally develop. To overcome this, it has been 
proposed that measuring the T-cell response from lymph nodes draining the cutaneous sites 
of vaccination could be a sensitive assessment of immunogenicity developed by a melanoma 
vaccine administration (Slingluff Jr et al., 2008).  
Surprisingly, in some studies, induction of T-cell responses is not reliably associated with 
clinical tumour regression. As an example, vaccination with a modified gp100 peptide led to 
detectable CTL responses in the peripheral blood in over 90% of patients, but no clinical 
tumour regressions were observed. In another section of the same study, in which patients 
were received in addition high-dose of IL-2, there was a noticeable clinical tumour 
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regressions in 41% of patients, but T-cell responses were registered in only a small minority 
of patients (Rosenberg et al., 1998). Nevertheless, optimization of cancer vaccines will 
benefit from complex immune monitoring in multiple lymphoid compartments. Critical 
compartments for immune monitoring are comprising the lymph node as the site of T-cell 
response induction, the circulating peripheral blood lymphocytes (PBL) and the sites of 
primary and metastatic tumour as well (Slingluff Jr et al., 2008). Cancer vaccine clinical trials 
meant to induce T cell - mediated immunity are evaluated routinely by measuring the 
immune response in the PBL but not in the other two compartments. Some murine and 
human studies suggest that, even after a single immunization, epidermal Langerhans cells 
migrate and mature to draining nodes within hours, with a peak of T-cell accumulation in 
the draining lymph nodes at day 5–10 (Macatonia et al., 1987; Rosato et al., 1996; Yoshizawa 
et al., 1991). Thus, it has been hypothesized that evaluation of T-cell responses in the 
draining lymph node would permit a more sensitive measure of immunogenicity than 
evaluation of T-cell responses in the peripheral blood alone (Slingluff Jr et al., 2008). From 
patients enrolled in clinical trials of experimental melanoma peptide vaccines, sentinel 
immunized nodes (SIN) were harvested a week after the third vaccine round, in order to 
identify the peak time of T-cell accumulation. T-cell responses to defined peptides were 
detected 25% more often in the SIN compared with PBL. Combining the evaluation of PBL 
and SIN leads to increased sensitivity in detecting immunogenicity to nearly 75%. 
Moreover, the T-cell responses in a SIN were detected at a high level, when they were either 
absent or at low level in both blood and the involved lymph node prior to vaccination 
(Yamshchikov et al., 2001). This finding supports the continued evaluation of the SIN for 
monitoring T-cell responses to melanoma peptide vaccination. 
The challenges in melanoma vaccination are extensive, but they can be surmounted by a 
thorough understanding of immune mechanisms and proper guided clinical trials (Sondak 
et al., 2006). We can add to these relevant conclusions that careful monitoring of anti-tumour 
T-cell responses, directed toward tumour peptides/proteins/antigens, developing complex 
monitoring of the patient’s immune responses and establishing an intricate relation with 
clinical end points would definitely add important value to vaccination treatment in 
melanoma. 
3.4 Immune-therapy with cytokines 
Using combinations of chemotherapy with cytokines, clinical parameters of patients were 
improved. All the promising new therapeutic agents have to be related to identification of 
predictors of response leading towards personalized therapy. IL-2, IFN, IL-12 and other 
therapeutical combinations were used and monitoring their efficacy was performed using 
immune markers. 
Melanoma is resistant to standard chemotherapy, having a response rate for any single agent 
or combination of agents of 15% - 25%. Using combinations of chemotherapy, IFN and IL-2 the 
response rate was improved, but with no clear effect on overall survival (Chapman, 2007).  
3.4.1 IL-2 
Particularly IL-2 was involved in cutaneous melanoma immune-therapy in the last 20 years. 
Several years ago, it has been published that over the course of IL-2 based immunotherapy, 
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difficulties associated with the monitoring of anti-tumour immune responses arise 
(Andersen et al., 2003). A couple of years ago, despite promising phase II data, phase III 
studies have failed to show meaningful clinical benefit for the combination of cytokines with 
cytotoxic chemotherapy (Andersen et al., 2003) and now the effort is focused on identifying 
predictors of therapeutic response, therefore an increased efficacy in term of patients benefit 
(Atkins, 2006). Following high-dose IL-2 administration, the number and frequency of 
regulatory T cells (Tregs) were monitored in patients with progressive disease and the 
values returned to normal in patients with objective clinical responses (Cesana et al., 2006) 
or the monitoring was performed analyzing pSTAT5 in patient’s PBMC (Varker et al., 2006). 
Investigating patients with intralesional IL-2 treatment authors pointed out an increase in 
the CD4+/CD8+ ratio and a rise in the percentage of CD25+ cells in the CD4+ population, 
the majority of this population being activated T cells. The local IL-2 is able to induce a 
systemic beneficial immunological effect (Green et al, 2008).  
There are several studies that combine IL-2 with vaccines or growth factors. Thus when 
combining IL-2 with Melan-A-specific CTL, an anti-tumour response was elicited and 
monitored by an elevated frequency of circulating Melan-A + T cells, an increase in 
eosinophils and a selective loss of Melan-A expression in lymph node metastases without 
major adverse effects (Makensen et al., 2006). Another phase II clinical trial using a 
combination of IL-2 with GM-CSF (Elias et al., 2005), showed the DC activation, and an 
increased IL-2 receptor expression on T cells. The treatment was intended to high-risk 
melanoma patients and no significant side-effects were registered. Continuing their work 
(Elias et al., 2008) the same group reported the clinical benefit of using GM-CSF and IL-2 
with or without autologous vaccine in patients with resected melanoma. Just recently 
published, a phase III clinical trial (Schwartzentruber et al., 2011) with melanoma patients 
diagnosed in stage III and IV (ClinicalTrials.gov number, NCT00019682) receiving IL-2 and 
gp100 peptide vaccine showed that the response rate was improved and progression-free 
survival increased when combining these two immune therapeutical agents in comparison 
to IL-2 administered individually. 
3.4.2 IFN 
IFN-alpha is one of the most used immune-therapy agent and IFN treatment was 
demonstrated to significantly prolong relapse-free survival of patients diagnosed in stage 
IIB-III melanoma. When these patients were subjected to IFN-alpha2b therapy, a significant 
decrease of serum levels of immunosuppressive / tumour angiogenic/growth stimulatory 
factors (Vascular Endothelial Cell Growth Factor - VEGF, Epidermal Growth Factor - EGF 
and hepatocyte growth factor- HGF), increased levels of anti-angiogenic IFN-gamma 
inducible protein 10 (IP-10) and IFN-alpha along with their good clinical outcome 
(Yurkovetski et al., 2007) have been noted. As therapeutic monitoring tools, gene microarray 
analysis of the transcriptional profile of peripheral T cells, NK, and monocytes as a response 
to IFN-alpha therapy was demonstrated. Authors point out that the transcriptional profiles 
of PBMCs from IFN-alpha treated patients may be a useful predictor of the in vivo response 
of immune cells to IFN-alpha immunotherapy (Zimmerer et al., 2008). 
In a prospective neoadjuvant trial for IFNalpha2b, in which tissue samples were obtained 
before and after therapy, double immunohistochemistry for pSTAT1 and pSTAT3 was done. 
The pSTAT1/pSTAT3 ratios were augmented by IFNalpha2b both in melanoma cells and in 
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lymphocytes. Antigen peptide transporter 2, involved in the transport of various molecules 
across extra- and intra-cellular membranes (TAP2), was augmented by IFNalpha2b (but not 
TAP1 and MHC class I/II). The authors prove that IFNalpha2b significantly modulates the 
balance of STAT1/STAT3 in tumour cells and host lymphocytes, mechanisms that lead to 
the up-regulation of TAP2 and an augmented host antitumour response. The baseline of 
pSTAT1/pSTAT3 ratio in tumour cells may serve as a useful predictor of the therapeutic 
effect of IFN (Wang et al., 2007).  
3.4.3 IL-12  
IL-12 as therapy agent has both immunoregulatory function and anti-tumour activity 
mediated by stimulation of T and NK effector cells. Authors propose IL-12 as a therapeutical 
agent using a protocol to pre-screen melanoma patients for IL-12Rbeta2 expression to 
stratify the potential responders, administrate non-toxic doses and target IL-12R+ tumour 
cells, by local administration or injection of IL-12 fused to an antibody specific to tumour 
cells (Cocco et al., 2009). This interleukin is recently highly involved in cutaneous melanoma 
genetic therapy (see section). 
Cytokines are the molecular messengers that control almost any physiological function of 
immune cells and are involved in the neoplastic transformation of normal cells. Cytokines 
are involved in immune recognition, proliferation and effector functions of immune cells. 
From the beginning of the research in the biomarkers discovery field, cytokines and their 
receptors were searched in association to diagnostic, prognostic and/or therapy. Some of 
the cytokines became therapeutic agents, such as IL-2 and all the recent papers on the 
clinical efficacy of cytokines state that this type of immune-therapy gets its best place in 
therapeutical combinations. 
3.5 Targeting innate-immunity 
Toll-like receptors (TLR) are involved in the regulation and activation of both innate and 
adaptive immunity (Takeda et al., 2003), activating therefore the anti-tumoural activity of 
lymphocytes. In a recently published experimental model, synthetic agonists for TLR 3 and 
9 activated T cells improving their anti- melanoma activity (Amos et al., 2011) action that 
was supposed to take place via IFN-γ production. Moreover, TLR agonists can be good 
adjuvants in immune therapy. 
In a phase I clinical study with synthetic agonists of TLR 9 in advanced stages melanoma, a 
complete regression was obtained in one of the 5 tested patients. The immune monitoring 
was performed testing the serum concentrations of IL-6, IP-10, IL-12p40, TNF-alpha. The 
immune treatment proved good clinical response metastatic melanoma (Hofmann et al., 
2008). In a case study with a long period of treatment with TLR 9 agonist, it was reported 
that this compound induced strong tumour-specific immune response (Stoeter et al., 2008). 
A phase II clinical study using TLR 7 agonist administered in patients with metastatic 
melanoma published its results several years ago and showed a prolonged stabilization of 
the disease. Monitoring was performed measuring IFN and IP-10 and peripheral blood 
immune cells. Out of 13 patients, 4 had disease stabilization and one patient had a partial 
remission. CD86 expression on monocytes, IFN and IP-10 increased in most patients upon 
therapy (Dummer et al., 2008). 
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Combining DTIC with the topical application of a TLR agonist in an experimental model 
decreased the rate of tumour evolution and enhanced animal survival. In this study authors 
stated that the topical application of TLR agonist is more efficient than intratumoural 
inoculation. Immune monitoring showed that the antitumour effect is both CD4+ and CD8+ 
dependent, the B220+CD8+ subset of dendritic cells and NK1.1+ CD11c+ cells within the 
tumours were enhanced, thus a more effective immune response against melanoma (Najar 
& Dutz, 2008). When using another combination, namely topical application of TLR agonist 
and intra-tumoural inoculation of DCs a good immune response was obtained in an 
experimental model. This therapeutical combination resulted in a significant tumour 
regression and a therapeutical approach to be considered (Lee et al., 2007). 
In patients topically treated with TLR-7 agonists, the tumour infiltrate showed an increased 
population of CD3+, CD4+ and CD8+ T cells, cytotoxic T cells (TIA-1+, granzyme B+) and 
DC CD 123+ (Wolf et al., 2007). 
Overall, agonists that address Toll-like receptors act through enhancing anti-tumoural 
cellular activity and systemically by an increased production of cytokines and chemokines.  
3.6 Gene therapy 
In cutaneous melanoma the genetic patterns can be the starting point for developing new 
molecular targets for therapeutic intervention and diagnostic biomarkers for melanoma (Su 
et al., 2009). In melanoma several altered tumour suppressor genes (p53, CDKN2A, Ras) are 
frequently found in primary and metastatic melanomas and are incriminated for the 
invasive and metastatic potential (Lalou et al., 2010). Gene therapy has been a rapidly 
expanding field in cancer in the last years and evermore in cutaneous melanoma. In this 
disease, the gene therapy tendency is the manipulation of interleukin genes. Thus, this year, 
in mouse experimental models, the results of an interesting attempt of gene therapy have 
been published. DCs genetically altered to express IL-12 can induce cytotoxic CD8+ T cell 
antitumoural response. The immune-intervention has good therapeutical potential as 
peptides from tumour-associated stromal antigens can be recognized by peripheral blood 
CD8+ T cells from melanoma patients after in vitro stimulation (Zhao et al., 2011). In 
addition, this year, in IL-10-knockout mouse model it was demonstrated that these mice are 
more resistant to melanoma development, IL-12 and IFN-γ being secreted in increased 
quantities (Marchi et al., 2011). The authors have constructed a plasmid containing the 
murine IL-10 receptor. When treating the animals with this plasmid, their survival time 
extended post-inoculation with melanoma cell lines. Associating this gene therapy with IL-
12 gene therapy a beneficial therapeutical response could be obtained. 
Several years ago, the first report on the clinical safety of in vivo particle-mediated epidermal 
delivery (PMED) as a cancer gene therapy was published (Ryan et al., 2007). PMED is 
transferring to specific location genes without viral carrier, the procedure has no viral 
potential risks, presents multipotency in cell transfections and multi gene transfer. For this 
therapy, authors have chosen the genes for gp100 and GM-CSF. Using PMED, they 
delivered these genes to patients with melanoma. The immune monitoring of treated 
patients was multifaceted: a complex array of auto-antibodies, rheumatoid factor, peripheral 
blood lymphocytes CD69+ expression, CD1a+ dendritic cells in biopsies and so on. The first 
reported clinical trial transferring cDNAs for gp100 and GM-CSF to patients concluded that 
the procedure is safe and that it can induce transgene expression in the treated skin. 
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Gene therapy’s future and clinical benefit rely on the genotypic pattern of the patients. 
Therefore, several years ago it was reported on a large number of patients that the presence 
of chemokine receptor 5 gene (CCR5Delta32) polymorphism in patients diagnosed in 
advanced stages subjected to immunotherapy can indicate a decreased survival and, 
moreover, this gene pattern can be useful in selecting patients that have the best clinical 
outcome when subjected to immune therapy (Ugurel et al., 2007). 
Gene therapy has still to overcome clinical compliances and prove its lack of deleterious 
side-effects in order to conquer the immune therapy field in melanoma. 
3.7 Epigenetic therapy 
The investigations regarding cancer alterations have gained, in the recently years, a new 
thrilling way for defining novel clinical settings and therapies, namely the epigenetic 
research (Selcuklu & Spillane, 2008). In contrast with genetic events involving irreversible 
changes in the genome (e.g. deletions), epigenetic changes imply alterations in gene 
expression without modifications of the primary DNA sequence. In addition, an epigenetic 
profile should be concurrently self-perpetuating, heritable and reversible (Bonasio et al., 
2010; Howell et al., 2009). It is now accepted that malignant transformation of melanocytes 
occurring in cutaneous melanoma, is greatly accompanied by epigenetic modifications 
(Sigalotti et al., 2010). Such “epimutations” could be turned on in defining new therapies 
considering the high incidence, poor prognosis and resistance of metastatic melanoma to 
conventional therapies (Howell et al., 2009). 
The epigenetic modifications of mammalian DNA involve at a glance cytosines methylation 
from CpG dinucleotide islands, deacetylation of DNA-binding histones and noncoding RNA 
profiles (miRNA) (Esteller, 2007). However, it is still under debate if post-translational 
modifications of histones and miRNAs signature are considered epigenetic events; in addition, 
some authors sustain that methylation of cytosines C-5 is the only clearly identified epigenetic 
modification of DNA in mammalian cells (Howell et al., 2009; Bird, 2002). 
The DNA methylation process is under the balance of complex equipment consisting of 
DNA methyltransferases (DNMTs) responsible for genome-wide DNA methylation 
patterns, and methyl-CpG-binding proteins dedicated to deciphering the methylation 
profile. A normal cellular development is characterized by a properly specified DNA 
methylation outline but any deviation from this established pattern is one of the important 
characteristics for the majority of human cancers. As a general characteristic, neoplastic 
transformation is accompanied by complex disturbances of the genomic DNA methylation 
homeostasis. There is a variable and still relatively unknown extent of methylation range, 
(Howell et al., 2009) with both gene-specific hypermethylation and genome-wide 
hypomethylation as a consequence (Sigalotti et al., 2010; Jones & Baylin, 2007). 
Histones are DNA-binding proteins mostly responsible for packaging of DNA into 
chromatin (Bird, 2002) and DNA segregation from the transcriptional machinery (Jones & 
Baylin, 2007). The acetylated histones at lysine residues are associated with transcriptionally 
active DNA whereas histone deacetylation means transcriptionally inactive DNA.  
Histone deacetylases (HDACs) are involved in the development of various tumours through 
the alteration of normal gene expression and inhibition of DNA repair machinery (Hadnagy 
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et al., 2008) thus representing one of the main epigenetic targets in cancer therapy (Howell et 
al., 2009). Despite the substantial information regarding the DNA methylation pattern in 
cutaneous melanoma, the existing data for abnormal post-translational modifications of 
histones are limited and someway indirect; these resulting from subsequent observations 
post-therapy with pharmacologic inhibitors of histone-modifying enzymes (i.e., HDACi) 
(Sigalotti et al., 2010). 
Although relatively new entry and still not fully accepted as steady players in the epigenetic 
research of cancer, microRNAs gained a special attention in melanoma studies. MicroRNAs 
(miRNAs) are endogenous small noncoding RNAs (≈22-nt) with a regulatory nature upon 
gene expression by inhibiting mRNA translation (Bartel, 2004) or by causing mRNA 
degradation (Sood et al., 2006). Nowadays there are hundreds of confirmed miRNAs in 
humans (Molnár et al., 2008) and current evidence is emerging to the important role of 
particular miRNAs in human cancer epigenetic pathogenesis (Howell et al., 2009). Thus, 
data regarding miRNA deregulation in melanoma is rather limited, the majority of studies 
about miRNA involvement in tumourigenesis are completed especially on melanoma cell 
lines. However, the altered pattern of miRNA in melanoma seems to be related with 
apoptosis (miR-15b), cell cycle (miR-193b) and invasion/metastasis (miR-182) (Satzger et al., 
2009; Chen et al., 2010; Segura et al., 2009). 
Taking into account the epigenetic deregulation imprinting described so far in cutaneous 
melanoma, the intervention therapy from this point of view is focused on the DNMT and/or 
HDAC inhibitors. DNMT inhibitors (Lyko & Brown, 2005) are consisting of cytosine 
analogues and thus mimic the substrate for DNMT. 5-azacytidine (Vidaza), 5-AZA-CdR 
(Dacogen), S110 and zebularine (Yoo et al., 2007) are among the most accepted cytosine 
analogues exploited in melanoma epitherapeutics. Such analogues are incorporated in 
genomic DNA during the S-phase of the cell cycle and upon methylation a covalent bond 
between modified DNA and enzyme are formed, resulting the inactivation of DNMT, 
cellular depletion of enzyme and, therefore, the demethylation of DNA (Schermelleh et al., 
2005). Along with DNMT inhibitors, histone deacetylase inhibitors (HDACi) have been 
hailed as a powerful new class of anticancer drugs. One of these inhibitors, trichostatin A 
(TSA), is thought to promote immune responses against tumours by an epigenetic control of 
cell cycle progression in G1 and G2-M phase, leading the growth arrest, differentiation or 
apoptosis (Setiadi et al., 2008). TSA treatment enhance the expression of some components 
of the antigen processing equipment and of MHC class I molecules on the carcinoma cell 
surface, leading to an enhanced vulnerability to killing by antigen-specific CTLs. Thus, 
immunotherapeutic anti-tumour approaches for eliminate cell cancers could be perceived 
differently by these novel insights defined by epigenomics (Setiadi et al., 2008). 
4. Summary 
Immune-therapy in cutaneous melanoma has to evaluate antitumour efficacy, 
autoimmunity, and reconstitution of a functioning immune system. Clinical studies and 
experimental research have gathered significant results to conclude that complex vaccines, 
combination of different therapeutical approaches, dendritic cell–based therapies in 
conjunction with co-stimulatory molecules, are superior to conventional immunization 
protocols in the induction of tumour-specific immune responses.  
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Target 
Agent 
Immune markers 
therapy monitoring 
Comments Stage Ref. 
Immunomodulatory antibodies 
CTL-4  
 
peripheral CD4+ CD8+ 
T, CD8+; tumour 
infiltrates 
Progression-free and 
overall survival 
FDA 
appr. 
Robert et al., 
2011 
Anti-TLR synthetic agonists 
TLR 7  IFN, IP-10, peripheral 
blood immune cells, 
intratumoral infiltrates 
Stabilization of the 
disease 
Phase II Dummer et 
al., 2008 
Wolf et al., 
2007 
TLR 3  
TLR 9 
anti-tumoral T cells, 
IFNγ  
Good clinical 
response metastatic 
melanoma 
Phase I Amos et al., 
2011 
Hofmann et 
al., 2008 
Stoeter et al., 
2008 
Dendritic cell 
Dex T and NK cells Activation of T-cells 
and NK cells 
Phase I Escudier et 
al., 2005 
Hao et al., 
2006 
Viaud et al., 
2010 
DC Cell mediated anti-
tumoral immune 
response  
DTH reaction 
Good clinical 
outcome 
Pilot 
Phase I 
Phase II 
David et al., 
2006 
Mayordomo 
et al., 2007 
Vaccines with melanoma antigens 
HSP  T cell stimulation Longer survival Phase 
III 
Rivoltini et 
al., 2003, 
Lewis, 2004 
gp100 
peptide 
T cytotoxic activation Tumour regression Phase 
III 
Schwartzent
ruber et al., 
2011 
Cytokines 
IL-2 Number and frequency 
of Tregs 
Good clinical 
responses 
FDA 
appr. 
Cesana et 
al., 2006 
IL-2 and 
Melan-A-
specific 
CTL 
Circulating % of  
Melan-A + T cells, 
eosinophils  
Good clinical 
responses 
Phase II Makensen et 
al., 2006 
IL-2 and 
gp100 
vaccine 
CD4, CD8, Tregs Response rate  
and progression- 
free survival 
increased 
Phase 
III 
Schwartzent
ruber et al., 
2011 
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IFN-
alpha2b 
IP-10, VEGF, EGF, HGF, 
peripheral NK, T and 
monocytes  
Tissue pSTAT1/pSTAT3  
Prolong relapse-free 
survival Adjuvant 
therapy Predictor of 
the therapeutic effect 
FDA 
appr. 
Yurkovetski 
et al., 2007 
Wang et al., 
2007 
IL-12 Stimulation of T and NK Marker for 
stratifying the 
potential responders 
Phase 
I/II 
Cocco et al., 
2009 
Gene therapy 
DC 
express 
IL-12 
CD8 anti-tumoral 
response 
Extended survival 
time 
Animal 
models 
Zhao et al., 
2011 
Plasmid - 
IL-10R 
gene 
IL-12 and IFN secretion Extended survival 
time 
Animal 
models 
Marchi et 
al., 2011 
Epigenetic immune-therapy 
TSA CTL antigen-specific Decreased invasion 
and cell cycle arrest 
Cellular 
models 
Setiadi et al., 
2008 
Table 1. Immune-therapies and immune efficacy markers in cutaneous melanoma  
(FDA appr. = FDA approval; Dex.= Dexosomes) 
The immune parameters that efficiently monitor the evolution of the patients subjected to 
immune therapy comprise circulatory and tissue immune-related components. Hundreds of 
opened/approved clinical trials testing immune-therapy efficacy in cutaneous melanoma 
are using the immune monitoring of enrolled patients. All the authors agree that when 
using immuno-therapeutic agents in cutaneous melanoma, the systemic immune response is 
to be monitored (for a “at a glance” perspective see Table 1).  
5. Conclusions and future perspectives 
All the recent studies and research regarding melanoma immunotherapy have 
demonstrated that complex vaccines and the combination of different approaches, such as 
the use of dendritic cell vaccines in conjunction with co-stimulatory molecules, are superior 
to conventional immunization protocols in the induction of tumour-specific immune 
responses. Evaluation of clinical parameters and patient’s-specific real-time immunological 
parameters may identify the most effective immunotherapy in melanoma. There are at least 
hundreds of approved clinical trials in immune-therapy related to cutaneous melanoma and 
the majority is foreseeing the utility, if not actively using, immune monitoring of enrolled 
patients.  
Besides the approved cytokines in the immune-therapy of cutaneous melanoma, antibodies 
targeting CTLA-4 have demonstrated their feasibility, safety, and clinical activity and were 
approved as therapeutic agent in melanoma. 
The failure of immune-therapies underlined in various sections probably reside in the 
immunological profile of the patient, thus the need of finding predictive markers is 
mandatory in order to detect treatment outcome in melanoma. Molecules that arise in the 
processes of neoplastic transformation, invasion and metastasis, are interrelated with the 
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components of the immune responses. Future molecular patterns of cutaneous melanoma 
will compulsory comprise immune-related molecules. Nowadays forces are gathered to 
search for immune markers that specifically indicate the disease stage and eventually 
develop new targets for personalized efficient therapy.  
We expect melanoma vaccination to become clinical routine therapy in the very near future. 
In this respect, a thorough monitoring is foreseen and in the future-to-be biomarkers panel, 
immune markers will have their foremost role. As the pathophysiology of melanoma is 
complex it is more convincing that only a combination of markers from genomics, 
transcriptomics, metabolomics and proteomics can cover the array of processes comprising 
the development of cutaneous melanoma. In this future set of markers, MHC allele 
expression in the individual patient's tumour and T-cell mediated immune responses 
specific for autologous melanoma will be evaluated.  
As the incidence of melanoma is steadily increasing, an individualized immunological 
profile of the patient can reorient/personalize immune-therapy and monitor the efficacy of 
the treatment approach and the molecular diagnostic of cutaneous melanoma will have 
important immune components. Although far from being exhaustive, this chapter was 
intended to overview the main immune therapy possibilities used in the management of 
cutaneous melanoma patient. In all the stages of cutaneous melanoma development, 
immune elements are involved; they are associated with tumour initiation, tumour evasion, 
suppressed immune response and probably many more unknown mechanisms.  
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